BMJ Open:急性冠脉综合征患者临床特征、处理及1年预后

2016-01-13 phylis 译 MedSci原创

目的:评估伊朗急性冠脉综合征住院(ACS)患者的特征,管理及出院1年后的预后。设置:伊朗伊斯兰共和国5个主要城市的11家三级医疗医院。参与者:年龄≥20和≤80岁的出院确诊为ACS的患者,包括ST段抬高心肌梗死(STEMI)、非ST段抬高型心肌梗死(NSTEMI)和高危不稳定型心绞痛(HR-UA)。主要和次要结果措施:随访患者,药物的应用和研究的终点为出院后1个月和1年的终点。该研究的主要终点是出

目的:评估伊朗急性冠脉综合征住院(ACS)患者的特征,管理及出院1年后的预后。

设置:伊朗伊斯兰共和国5个主要城市的11家三级医疗医院。

参与者:年龄≥20和≤80岁的出院且被确诊为ACS的患者,包括ST段抬高心肌梗死(STEMI)、非ST段抬高型心肌梗死(NSTEMI)和高危不稳定型心绞痛(HR-UA)。

主要和次要结果措施:随访患者,药物的应用和研究的终点为出院后1个月和1年的终点。该研究的主要终点是出院后1年主要不良心脑血管事件(MACCEs)、死亡(心脏和非心脏死亡)、ACS和脑血管病(脑卒中或短暂性脑缺血发作)。次要终点是住院因充血性心力衰竭入院,冠状动脉旁路移植术手术或经皮冠状动脉介入治疗(PCI),和严重出血及微出血发生。

结果:共有1799名(25.7%为STEMI和74.3% HR-UA/NSTEMI)出院确诊为ACS的患者被纳入最终分析。在住院治疗过程中,大多数的患者接受阿司匹林(98.6%)、氯吡格雷(91.8%)、抗凝药(93.4%)、他汀类药物(94.3%)和β-受体阻滞剂(89.3%)。62.6%的STEMI患者进行再灌注治疗(46.3%为溶栓治疗和17.3%进行PCI)。平均D2B和D2N时间分别为82.9和45.6 min。研究中,在HR-UA/NSTEMI和STEMI组患者进行冠脉造影术的比例分别为64.7%和79.5%。出院后的12月内,15%的患者发生MACCEs。

结论:研究表明,伊朗患者各种ACS的患者组成与发达欧洲国家相似,与中东和非洲等发展中国家ACS组成类型不同。研究还发现ACS患者在住院治疗的过程中是按照指南推荐进行治疗的。

原文出处:

Kassaian SE, Masoudkabir F, et al. Clinical characteristics, management and 1-year outcomes of patients with acute coronary syndrome in Iran: the Iranian Project for Assessment of Coronary Events 2 (IPACE2). BMJ Open. 2015 Dec 15.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1842850, encodeId=8780184285099, content=<a href='/topic/show?id=112222886b8' target=_blank style='color:#2F92EE;'>#临床特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22886, encryptionId=112222886b8, topicName=临床特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Sat Nov 19 09:11:00 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726015, encodeId=610c1e26015dc, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Jun 06 02:11:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847865, encodeId=1842184e865d7, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Aug 29 13:11:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430576, encodeId=d00914305e625, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Jan 15 12:11:00 CST 2016, time=2016-01-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1842850, encodeId=8780184285099, content=<a href='/topic/show?id=112222886b8' target=_blank style='color:#2F92EE;'>#临床特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22886, encryptionId=112222886b8, topicName=临床特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Sat Nov 19 09:11:00 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726015, encodeId=610c1e26015dc, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Jun 06 02:11:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847865, encodeId=1842184e865d7, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Aug 29 13:11:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430576, encodeId=d00914305e625, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Jan 15 12:11:00 CST 2016, time=2016-01-15, status=1, ipAttribution=)]
    2016-06-06 feather89
  3. [GetPortalCommentsPageByObjectIdResponse(id=1842850, encodeId=8780184285099, content=<a href='/topic/show?id=112222886b8' target=_blank style='color:#2F92EE;'>#临床特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22886, encryptionId=112222886b8, topicName=临床特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Sat Nov 19 09:11:00 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726015, encodeId=610c1e26015dc, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Jun 06 02:11:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847865, encodeId=1842184e865d7, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Aug 29 13:11:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430576, encodeId=d00914305e625, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Jan 15 12:11:00 CST 2016, time=2016-01-15, status=1, ipAttribution=)]
    2016-08-29 gaoxiaoe
  4. [GetPortalCommentsPageByObjectIdResponse(id=1842850, encodeId=8780184285099, content=<a href='/topic/show?id=112222886b8' target=_blank style='color:#2F92EE;'>#临床特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22886, encryptionId=112222886b8, topicName=临床特征)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Sat Nov 19 09:11:00 CST 2016, time=2016-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1726015, encodeId=610c1e26015dc, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Mon Jun 06 02:11:00 CST 2016, time=2016-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1847865, encodeId=1842184e865d7, content=<a href='/topic/show?id=2977356edc' target=_blank style='color:#2F92EE;'>#BMJ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3567, encryptionId=2977356edc, topicName=BMJ)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=148754, createdName=gaoxiaoe, createdTime=Mon Aug 29 13:11:00 CST 2016, time=2016-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1430576, encodeId=d00914305e625, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Jan 15 12:11:00 CST 2016, time=2016-01-15, status=1, ipAttribution=)]

相关资讯

NEJM:急性冠脉综合征后应用依折麦布-他汀类药物联合治疗

背景: 他汀类药物治疗可降低低密度脂蛋白(LDL)胆固醇水平与心血管事件的风险,但加入一种非他汀类药物依折麦布后,是否可以减少肠道胆固醇的吸收,以及进一步降低心血管事件发生率是未知的。    方法: 研究人员进行了这项涉及18144患者的双盲、随机试验,这些患者都曾在过去的10天内因急性冠脉综合征而入院,如果他们正在接受降脂治疗他们的LDL胆固醇水平为50-100mg

JACC:阿哌沙班单抗或双重抗血小板治疗急性冠脉综合征效果

    目前,出血情况限制了急性冠脉综合征(ACS)的抗凝治疗。该研究对ACS后伴随抗血小板治疗是否会影响阿哌沙班的效果进行了调查。    本研究旨在探讨使用阿司匹林或阿司匹林加氯吡格雷治疗的高危急性冠脉综合征患者被随机分配接受每日两次阿哌沙班5毫克或安慰剂的效果。在事后分析中,研究人员评估是否阿哌沙班的疗效和安全性会随着伴随抗血小板方案的使用而变化,通过有

BMJ Open:男性易发生不稳定型心绞痛

不稳定型心绞痛,是介于劳累性稳定型心绞痛与急性心肌梗死和猝死之间的临床表现。主要包括初发心绞痛、恶化劳力性心绞痛、静息心绞痛伴心电图缺血改变和心肌梗死后早期心绞痛。其特征是心绞痛症状进行性增加,新发作的休息或夜间性心绞痛或出现心绞痛持续时间延长。研究者在芬兰进行了一项基于人群的回顾性研究,探究因不稳定型心绞痛(UAP)的住院率的性别差异和年龄差异。该研究纳入了2000年5月-2009年10月间、≥

依折麦布药物或降低急性冠脉综合征患者的发病率!

依折麦布可降低糖尿病患者和急性冠脉综合征患者的心血管疾病的发病率,根据布莱根妇女医院的心内科医生Robert Giugliano博士进行的IMPROVE-IT试验指出,依折麦布比单独使用他汀类药物降低低密度脂蛋白胆固醇的效果更好,从而可降低糖尿病患者心脑血管事件发生的风险。“急性冠脉综合征,包括心肌梗塞和不稳定型心绞痛(心梗先兆),是世界各地民众死亡和心功能不全的主要原因,”Robert Giug

AIM:急性冠脉综合征(ACSs),早期介入治疗效果更好

随机临床试验发现,对于急性冠脉综合征(ACSs),与保守微创方法相比,早期介入治疗策略降低死亡率,心肌梗死(MI)和再住院概率,但这样的策略在现实生活中的设置的效果是未知的。该研究的目的是探讨早期 vs 保守的介入治疗对于ACSs患者的心血管不良后果。在该前瞻性队列研究中,研究人员的数据来自于ACSs患者接受所有急性介入治疗的数据,以及来自丹麦国家登记处住院,手术及结果的行政卫生保健数据。参与者为

NEJM:lixisenatide不能改变急性冠状动脉综合征合并2型糖尿病患者不良预后

背景:2型糖尿病患者,心血管疾病的发病率和死亡率较高,尤其是那些有心血管疾病的患者。研究者评估了胰高血糖素样肽1受体激动剂,利西拉肽对最近发生急性冠脉疾病的2型糖尿病患者心血管预后的影响。方法:研究者随机将180天内出现心肌梗死或不稳定心绞痛患者接受lixisenatide或安慰剂治疗,两组都进行当地的标准化护理。该试验有足够的统计效力评估lixisenatide优于或劣于安慰剂,即主要的复合终点